These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29133566)

  • 21. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
    Wei XC; Zhao MF; Li X; Xiao X
    J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
    Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
    Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Samtani MN; Flamm R; Kaniga K; Nandy P
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
    Hegde SS; Okusanya OO; Skinner R; Shaw JP; Obedencio G; Ambrose PG; Blais J; Bhavnani SM
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1578-83. PubMed ID: 22155835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
    Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM
    Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
    Drusano GL; Preston SL; Hardalo C; Hare R; Banfield C; Andes D; Vesga O; Craig WA
    Antimicrob Agents Chemother; 2001 Jan; 45(1):13-22. PubMed ID: 11120938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial dosage regimen of vancomycin for septic shock patients: a pharmacokinetic study and Monte Carlo simulation.
    Katip Bpharm W; Jaruratanasirikul S; Pattharachayakul S; Wongpoowarak W; Jitsurong A
    J Med Assoc Thai; 2014 Nov; 97(11):1209-19. PubMed ID: 25675687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Surber J; Mehra P; DeAnda C; Bulitta JB; Corey GR
    Antimicrob Agents Chemother; 2011 Feb; 55(2):583-92. PubMed ID: 21115795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
    Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against
    Ji XW; Xue F; Kang ZS; Zhong W; Kuan IH; Yang XP; Zhu X; Li Y; Lv Y
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D; van Ogtrop ML; Peng J; Craig WA
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.
    Meagher AK; Passarell JA; Cirincione BB; Van Wart SA; Liolios K; Babinchak T; Ellis-Grosse EJ; Ambrose PG
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1939-45. PubMed ID: 17353238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the "MIC Creep" Phenomenon.
    Setiawan E; Suwannoi L; Montakantikul P; Chindavijak B
    Acta Med Indones; 2019 Jan; 51(1):10-18. PubMed ID: 31073101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
    Noviello S; Huang DB; Corey GR
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):793-803. PubMed ID: 30317894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
    Noviello S; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Scaramucci A; Torres A; Huang DB
    J Med Microbiol; 2020 Apr; 69(4):625-630. PubMed ID: 32195649
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.